Helperby Therapeutics announces study results active against the WHO Critical Priority Carbapenem resistant bacterial pathogens

Helperby Therapeutics announces study results demonstrating promise of its unique combination antibiotic therapy - active against the WHO Critical Priority Carbapenem resistant bacterial pathogens

The combination of azidothymidine (AZT) and low-dose colistin shows synergistic antibiotic activity against carbapenem and colistin-resistant Enterobacteriaceae (CRE) infections.

Click here to read the full paper